Rabbit Recombinant Monoclonal ICOS Ligand/ICOSL antibody. Carrier free. Suitable for IP, WB and reacts with Human samples.
IgG
Rabbit
pH: 7.2 - 7.4
Constituents: PBS
Liquid
Monoclonal
IP | WB | |
---|---|---|
Human | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Select an associated product type
Ligand for the T-cell-specific cell surface receptor ICOS. Acts as a costimulatory signal for T-cell proliferation and cytokine secretion (PubMed:11007762, PubMed:11023515, PubMed:30498080). Also induces B-cell proliferation and differentiation into plasma cells. Could play an important role in mediating local tissue responses to inflammatory conditions, as well as in modulating the secondary immune response by co-stimulating memory T-cell function (By similarity). In endothelial cells, required for proper neutrophil transmigration in response to chemoattractants, such as CXCL8/IL8 or N-formyl-methionyl peptides (fMLP) (PubMed:30498080).
B7H2, B7RP1, ICOSL, KIAA0653, B7H2, ICOSLG, KIAA0653, B7RP1, ICOSL, ICOS ligand, B7 homolog 2, B7-like protein Gl50, B7-related protein 1, B7-H2, B7RP-1
Rabbit Recombinant Monoclonal ICOS Ligand/ICOSL antibody. Carrier free. Suitable for IP, WB and reacts with Human samples.
IgG
Rabbit
pH: 7.2 - 7.4
Constituents: PBS
Liquid
Monoclonal
Yes
EPR20240
Affinity purification Protein A
Blue Ice
+4°C
Do Not Freeze
ab251502 is the carrier-free version of Anti-ICOS Ligand/ICOSL antibody [EPR20240] ab209262.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
This supplementary information is collated from multiple sources and compiled automatically.
The ICOS Ligand also known as ICOSL B7-H2 and HK53 is a critical component in immune system function. This protein with a molecular mass of approximately 65 kDa is expressed on professional antigen-presenting cells such as dendritic cells macrophages and B cells. It plays a significant mechanical role in the immune response by engaging with its counter receptor the ICOS protein present on the surface of activated T cells. This interaction supports the regulation of T cell activity influencing proliferation and cytokine production.
ICOSL contributes to the modulation of immune responses. By forming a complex with the active ICOS protein ICOSL is involved in the co-stimulation of T cells. This process is important for the development of T-cell-dependent immune responses and helps in promoting the survival and differentiation of T cells. Together the ICOS ligand and ICOS protein create a dynamic interaction that balances immune activation and tolerance which is essential for maintaining immune homeostasis.
The ICOS-ICOSL interaction plays an important role in the T-cell receptor (TCR) signaling pathway. This pathway is fundamental for the activation of T cells and subsequent immune response. ICOSL also connects to the PI3K/Akt pathway where it impacts cell survival and proliferation. ICOS and the PI3K/Akt pathway work together to influence various aspects of immune regulation and adaptive immunity.
ICOSL has a notable impact on autoimmune diseases and cancer. Its function in immune modulation when dysregulated can contribute to autoimmune conditions such as systemic lupus erythematosus. In this context the abnormal activation of the ICOS protein may exaggerate immune responses leading to pathology. In cancer high expression of ICOSL can support tumor progression by affecting the immune surveillance capability. These associations reveal ICOSL’s role in balancing immune activation and inhibition which is important in the context of disease.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using Anti-ICOS Ligand/ICOSL antibody [EPR20240] ab209262, the same antibody clone in a different buffer formulation.
Blocking and dilution buffer: 5% NFDM/TBST.
All lanes: Western blot - Anti-ICOS Ligand/ICOSL antibody [EPR20240] (Anti-ICOS Ligand/ICOSL antibody [EPR20240] ab209262) at 1/20000 dilution
All lanes: His-tagged recombinant human ICOS ligand/ICOSL protein at 0.01 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Predicted band size: 33 kDa
Observed band size: 50 kDa
Exposure time: 10s
This data was developed using Anti-ICOS Ligand/ICOSL antibody [EPR20240] ab209262, the same antibody clone in a different buffer formulation.
Blocking and dilution buffer: 5% NFDM/TBST.
ICOS ligand/ICOSL is highly glycosylated (PMID 11983910).
Observed band sizes: 60 kDa (glycosylated form); 35 kDa (non-glycosylated form).
All lanes: Western blot - Anti-ICOS Ligand/ICOSL antibody [EPR20240] (Anti-ICOS Ligand/ICOSL antibody [EPR20240] ab209262) at 1/1000 dilution
Lane 1: Untreated JAR (Human placenta choriocarcinoma cell line) whole cell lysate at 20 µg
Lane 2: JAR whole cell lysate treated with PNGase F at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Predicted band size: 33 kDa
Exposure time: 30s
This data was developed using Anti-ICOS Ligand/ICOSL antibody [EPR20240] ab209262, the same antibody clone in a different buffer formulation.
ICOS Ligand/ICOSL was immunoprecipitated from 0.35 mg of JAR (Human placenta choriocarcinoma cell line) whole cell lysate with Anti-ICOS Ligand/ICOSL antibody [EPR20240] ab209262 at 1/40 dilution. Western blot was performed from the immunoprecipitate using Anti-ICOS Ligand/ICOSL antibody [EPR20240] ab209262 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (VeriBlot for IP Detection Reagent (HRP) ab131366), was used for detection at 1/10000 dilution.
Lane 1: JAR whole cell lysate, 10 μg (Input).
Lane 2: Anti-ICOS Ligand/ICOSL antibody [EPR20240] ab209262 IP in JAR whole cell lysate.
Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of Anti-ICOS Ligand/ICOSL antibody [EPR20240] ab209262 in JAR whole cell lysate.
Blocking and dilution buffer: 5% NFDM/TBST.
Exposure time: 3 minutes.
All lanes: Immunoprecipitation - Anti-ICOS Ligand/ICOSL antibody [EPR20240] (Anti-ICOS Ligand/ICOSL antibody [EPR20240] ab209262)
Predicted band size: 33 kDa
Observed band size: 60 kDa
This data was developed using Anti-ICOS Ligand/ICOSL antibody [EPR20240] ab209262, the same antibody clone in a different buffer formulation.
Blocking and dilution buffer: 5% NFDM/TBST.
The level of ICOS Ligand/ICOSL expression can be elevated by TNF-alpha treatment (PMID: 11983910).
All lanes: Western blot - Anti-ICOS Ligand/ICOSL antibody [EPR20240] (Anti-ICOS Ligand/ICOSL antibody [EPR20240] ab209262) at 1/1000 dilution
Lane 1: Untreated HUVEC (Human umbilical vein endothelial cell line) whole cell lysate at 20 µg
Lane 2: HUVEC whole cell lysate treated with tumor necrosis factor-α (TNF-alpha, Recombinant human TNF alpha protein ab9642) 200 unit/ml for 24 hours at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Predicted band size: 33 kDa
Observed band size: 60 kDa
Exposure time: 30s
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com